AstraZeneca gives itself top marks for R&D productivity makeover — but the jury is still out
Is AstraZeneca a model for Big Pharma R&D success?
Looking over their numbers for Q3 last November, you’d be hard pressed to make that case. Five years after they promised to turn around a deeply troubled company, CEO Pascal Soriot and his executive crew were still on the defensive as they walked analysts through the latest slippage on the product revenue side of the business. Product sales were down 3%, following an 11% drop in H1. And after five years at the helm, Soriot was still not saying when the great decline would end.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.